A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility.
OBJECTIVE
To establish whether initial screening characteristics of normogonadotropic anovulatory infertile women can aid in predicting live birth after induction of ovulation with clomiphene citrate (CC).


METHODS
Prospective longitudinal single-center study.


METHODS
Specialist academic fertility unit.


METHODS
Two hundred fifty-nine couples with a history of infertility, oligoamenorrhea, and normal follicle-stimulating hormone (FSH) concentrations who have not been previously treated with any ovulation-induction medication.


METHODS
50, 100, or 150 mg of oral CC per day, for 5 subsequent days per cycle.


METHODS
Conception leading to live birth after CC administration.


RESULTS
After receiving CC, 98 (38%) women conceived, leading to live birth. The cumulative live birth rate within 12 months was 42% for the total study population and 56% for the ovulatory women who had received CC. Factors predicting the chances for live birth included free androgen index (testosterone/sex hormone-binding globulin ratio), body mass index, cycle history (oligomenorrhea versus amenorrhea), and the woman's age.


CONCLUSIONS
It is possible to predict the individual chances of live birth after CC administration using two distinct prediction models combined in a nomogram. Applying this nomogram in the clinic may be a step forward in optimizing the decision-making process in the treatment of normogonadotropic anovulatory infertility. Alternative first line of treatment options could be considered for some women who have limited chances for success.
Imani
Babak
B
Division of Reproductive Medicine, Rotterdam, The Netherlands.
Eijkemans
Marinus J C
MJ
te Velde
Egbert R
ER
Habbema
J Dik F
JD
Fauser
Bart C J M
BC
D000022:Abortion, Spontaneous / Q000453:epidemiology; D000568:Amenorrhea / Q000097:blood / Q000188:drug therapy*; D002996:Clomiphene / Q000627:therapeutic use*; D004542:Ejaculation; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007231:Infant, Newborn; D007247:Infertility, Female / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D020738:Leptin / Q000097:blood; D008297:Male; D016017:Odds Ratio; D009839:Oligomenorrhea / Q000097:blood / Q000188:drug therapy*; D010060:Ovulation / Q000187:drug effects / Q000502:physiology; D010062:Ovulation Induction / Q000379:methods*; D011237:Predictive Value of Tests; D011247:Pregnancy; D011256:Pregnancy Outcome; D011336:Probability; D012189:Retrospective Studies; D013076:Sperm Count; D016896:Treatment Outcome
D005300:Fertility Agents, Female; D020738:Leptin; D002996:Clomiphene; D007334:Insulin-Like Growth Factor I; D005640:Follicle Stimulating Hormone